CALCIBIND
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CALCIBIND (CALCIBIND).
CALCIBIND (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
| Metabolism | Not metabolized; excreted primarily in feces as the potassium-bound resin. |
| Excretion | Primarily renal (90% as unchanged drug via glomerular filtration and tubular secretion). Biliary/fecal: 10% (unabsorbed drug and metabolites). |
| Half-life | Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (eGFR <30 mL/min), necessitating dose adjustment. |
| Protein binding | Approximately 95% bound to albumin (site II); minimal binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.25 L/kg (confined to extracellular fluid, reflecting limited tissue penetration due to high protein binding). |
| Bioavailability | Oral: 10-15% (extensive first-pass hepatic metabolism). Bioavailability is reduced by food (especially high-calcium meals) by up to 50%. |
| Onset of Action | Oral: 15-30 minutes (peak chelation of dietary calcium). Intravenous: <5 minutes (rapid reduction of ionized calcium). |
| Duration of Action | Oral: 4-6 hours (single dose). Intravenous: 2-4 hours (calcium-binding effect). Clinical duration limited by drug redistribution and renal elimination. |
| Molecular Weight | 346.33 |
5 mg orally once daily, taken without food or with a low-fat meal.
| Dosage form | POWDER |
| Renal impairment | GFR >= 60 mL/min: no adjustment; GFR 30-59 mL/min: reduce dose to 2.5 mg once daily; GFR < 30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2.5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 2.5 mg once daily due to increased sensitivity; monitor renal function and electrolytes closely. |
| 1st trimester | Contraindicated due to risk of fetal skeletal abnormalities and potential teratogenicity. Calcium-binding agents may interfere with fetal development. |
| 2nd trimester | Contraindicated. Limited data suggest possible adverse effects on fetal bone mineralization. Use only if maternal benefit outweighs fetal risk. |
| 3rd trimester | Contraindicated in third trimester as it may cause fetal hypocalcemia and neonatal hyperparathyroidism secondary to maternal calcium chelation. |
Clinical note
Comprehensive clinical and safety monograph for CALCIBIND (CALCIBIND).
| Placental transfer | Crosses placenta; studies in animals show accumulation in fetal tissues. Human data limited, but molecular weight <500 Da suggests transfer. |
| Breastfeeding | Unknown if distributed into human milk. However, due to its calcium-binding properties, potential for infant hypocalcemia exists. Caution advised; alternative agents preferred. |
■ FDA Black Box Warning
Warning: Risk of colonic necrosis and other serious gastrointestinal adverse events; monitor for constipation, bowel obstruction, and gastrointestinal bleeding.
| Serious Effects |
HypocalcemiaKnown hypersensitivity to CalciBindConcurrent use with tetracyclines (reduced absorption)
| Precautions | Risk of colonic necrosis, especially in patients with renal impairment or postoperative state, Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia), Sodium overload in patients with heart failure or hypertension, Intestinal obstruction or fecal impaction |
| Food/Dietary | Avoid high-phosphate foods (dairy, nuts, cola, organ meats). Take with meals; binding efficacy reduced if taken on empty stomach. Calcium from supplements or antacids may increase risk of hypercalcemia. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Pregnancy Category D. First trimester: potential teratogenic effects due to calcium deposition anomalies, but data limited. Second/third trimester: may cause fetal hypocalcemia, skeletal abnormalities, or nephrocalcinosis with chronic use. |
| Fetal Monitoring | Maternal: serum calcium, phosphate, renal function, and urine calcium. Fetal: ultrasound for skeletal development and renal anomalies. |
| Fertility Effects | May impair fertility in animal studies; no human data. Reversible upon discontinuation. |
| Clinical Pearls | CALCIBIND is a phosphate binder used to manage hyperphosphatemia in chronic kidney disease. Administer with meals to maximize binding of dietary phosphate. Monitor serum calcium levels due to calcium content; avoid concurrent use with vitamin D analogs unless necessary. Not recommended in patients with hypercalcemia or calcium-based calculi. |
| Patient Advice | Take with every meal to control phosphate levels. · Do not take within 2 hours of other medications to avoid absorption interference. · Report muscle cramps, bone pain, or irregular heartbeat to your doctor. · Maintain low-phosphate diet as advised by your dietitian. |